pembrolizumab
merck
['keynote-716', 'pembro']
big things happening at #asco22- long term follow up data in the keynote-716 study! pembro significantly improved 24-mo dmfs rate vs placebo (88.1% vs 82.2%) and reduced risk of recurrence, demonstrating its effectiveness as an adjuvant treatment 